|
Amphastar Slow to Report SAEs, Form 483 States
Amphastar Pharmaceuticals is slow to notify the FDA about complaints of serious and/or unexpected adverse events associated with its various generic drug products, a Form 483 states.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives